메뉴 건너뛰기




Volumn 8, Issue 15, 2019, Pages

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease

Author keywords

biomarker; diastolic dysfunction; neprilysin; smoking

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C;

EID: 85070590226     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.119.012943     Document Type: Article
Times cited : (19)

References (53)
  • 2
    • 84992053005 scopus 로고    scopus 로고
    • A test in context: neprilysin: function, inhibition, and biomarker
    • Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68:639–653.
    • (2016) J Am Coll Cardiol , vol.68 , pp. 639-653
    • Bayes-Genis, A.1    Barallat, J.2    Richards, A.M.3
  • 5
    • 0037425535 scopus 로고    scopus 로고
    • Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic
    • Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.
    • (2003) JAMA , vol.289 , pp. 194-202
    • Redfield, M.M.1    Jacobsen, S.J.2    Burnett, J.C.3    Mahoney, D.W.4    Bailey, K.R.5    Rodeheffer, R.J.6
  • 8
    • 77951625683 scopus 로고    scopus 로고
    • The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects
    • McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55:2140–2147.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2140-2147
    • McKie, P.M.1    Cataliotti, A.2    Lahr, B.D.3    Martin, F.L.4    Redfield, M.M.5    Bailey, K.R.6    Rodeheffer, R.J.7    Burnett, J.C.8
  • 9
    • 0030098039 scopus 로고    scopus 로고
    • History of the rochester epidemiology project
    • Melton LJ III. History of the rochester epidemiology project. Mayo Clin Proc. 1996;71:266–274.
    • (1996) Mayo Clin Proc , vol.71 , pp. 266-274
    • Melton, L.J.1
  • 15
    • 0027173606 scopus 로고
    • Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II
    • Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11:407–416.
    • (1993) J Hypertens , vol.11 , pp. 407-416
    • Richards, A.M.1    Wittert, G.A.2    Crozier, I.G.3    Espiner, E.A.4    Yandle, T.G.5    Ikram, H.6    Frampton, C.7
  • 16
    • 84867745957 scopus 로고    scopus 로고
    • The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
    • Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ACEI [Angiotensin-Converting—Enzyme Inhibitor]. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
    • (2012) Lancet , vol.380 , pp. 1387-1395
    • Solomon, S.D.1    Zile, M.2    Pieske, B.3    Voors, A.4    Shah, A.5    Kraigher-Krainer, E.6    Shi, V.7    Bransford, T.8    Takeuchi, M.9    Gong, J.10    Lefkowitz, M.11    Packer, M.12    McMurray, J.J.13
  • 20
    • 79955759374 scopus 로고    scopus 로고
    • Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum
    • discussion 2014
    • Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006–2013; discussion 2014.
    • (2011) Circulation , vol.123 , pp. 2006-2013
    • Borlaug, B.A.1    Redfield, M.M.2
  • 21
    • 79956194650 scopus 로고    scopus 로고
    • Natriuretic peptide metabolism, clearance and degradation
    • Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808–1817.
    • (2011) FEBS J , vol.278 , pp. 1808-1817
    • Potter, L.R.1
  • 25
    • 84865527834 scopus 로고    scopus 로고
    • Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction
    • Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M, Shah SJ. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:870–876.
    • (2012) Am J Cardiol , vol.110 , pp. 870-876
    • Anjan, V.Y.1    Loftus, T.M.2    Burke, M.A.3    Akhter, N.4    Fonarow, G.C.5    Gheorghiade, M.6    Shah, S.J.7
  • 26
    • 85050153568 scopus 로고    scopus 로고
    • A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction
    • Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–870.
    • (2018) Circulation , vol.138 , pp. 861-870
    • Reddy, Y.N.V.1    Carter, R.E.2    Obokata, M.3    Redfield, M.M.4    Borlaug, B.A.5
  • 28
    • 85021770915 scopus 로고    scopus 로고
    • Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction
    • Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6–19.
    • (2017) Circulation , vol.136 , pp. 6-19
    • Obokata, M.1    Reddy, Y.N.V.2    Pislaru, S.V.3    Melenovsky, V.4    Borlaug, B.A.5
  • 29
    • 77957907689 scopus 로고    scopus 로고
    • Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction
    • Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588–595.
    • (2010) Circ Heart Fail , vol.3 , pp. 588-595
    • Borlaug, B.A.1    Nishimura, R.A.2    Sorajja, P.3    Lam, C.S.4    Redfield, M.M.5
  • 30
    • 85009423905 scopus 로고    scopus 로고
    • Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study
    • Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825–838.
    • (2017) Circulation , vol.135 , pp. 825-838
    • Obokata, M.1    Kane, G.C.2    Reddy, Y.N.3    Olson, T.P.4    Melenovsky, V.5    Borlaug, B.A.6
  • 31
    • 0026093160 scopus 로고
    • Modulation of neurogenic inflammation by neutral endopeptidase
    • Nadel JA, Borson DB. Modulation of neurogenic inflammation by neutral endopeptidase. Am Rev Respir Dis. 1991;143:S33–S36.
    • (1991) Am Rev Respir Dis , vol.143 , pp. S33-S36
    • Nadel, J.A.1    Borson, D.B.2
  • 32
    • 0021823764 scopus 로고
    • Neutral metalloendopeptidase in human lung tissue and cultured cells
    • Johnson AR, Ashton J, Schulz WW, Erdos EG. Neutral metalloendopeptidase in human lung tissue and cultured cells. Am Rev Respir Dis. 1985;132:564–568.
    • (1985) Am Rev Respir Dis , vol.132 , pp. 564-568
    • Johnson, A.R.1    Ashton, J.2    Schulz, W.W.3    Erdos, E.G.4
  • 33
    • 0027475050 scopus 로고
    • Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology
    • Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87–146.
    • (1993) Pharmacol Rev , vol.45 , pp. 87-146
    • Roques, B.P.1    Noble, F.2    Dauge, V.3    Fournie-Zaluski, M.C.4    Beaumont, A.5
  • 35
    • 84877265606 scopus 로고    scopus 로고
    • Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction
    • Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013;6:279–286.
    • (2013) Circ Heart Fail , vol.6 , pp. 279-286
    • Ho, J.E.1    Lyass, A.2    Lee, D.S.3    Vasan, R.S.4    Kannel, W.B.5    Larson, M.G.6    Levy, D.7
  • 41
    • 84857857236 scopus 로고    scopus 로고
    • Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction
    • Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 998-1005
    • Ather, S.1    Chan, W.2    Bozkurt, B.3    Aguilar, D.4    Ramasubbu, K.5    Zachariah, A.A.6    Wehrens, X.H.7    Deswal, A.8
  • 42
    • 84971384492 scopus 로고    scopus 로고
    • Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction
    • Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4:441–449.
    • (2016) JACC Heart Fail , vol.4 , pp. 441-449
    • Hoeper, M.M.1    Meyer, K.2    Rademacher, J.3    Fuge, J.4    Welte, T.5    Olsson, K.M.6
  • 43
    • 84879748718 scopus 로고    scopus 로고
    • A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
    • Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
    • (2013) J Am Coll Cardiol , vol.62 , pp. 263-271
    • Paulus, W.J.1    Tschope, C.2
  • 44
    • 84953931431 scopus 로고    scopus 로고
    • LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice
    • Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T, Imaizumi S, Iwata A, Yahiro E, Saku K. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail. 2016;18:386–393.
    • (2016) Eur J Heart Fail , vol.18 , pp. 386-393
    • Suematsu, Y.1    Miura, S.2    Goto, M.3    Matsuo, Y.4    Arimura, T.5    Kuwano, T.6    Imaizumi, S.7    Iwata, A.8    Yahiro, E.9    Saku, K.10
  • 48
    • 77957228322 scopus 로고    scopus 로고
    • Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation
    • Pereira NL, Aksoy P, Moon I, Peng Y, Redfield MM, Burnett JC Jr, Wieben ED, Yee VC, Weinshilboum RM. Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol. 2010;49:864–874.
    • (2010) J Mol Cell Cardiol , vol.49 , pp. 864-874
    • Pereira, N.L.1    Aksoy, P.2    Moon, I.3    Peng, Y.4    Redfield, M.M.5    Burnett, J.C.6    Wieben, E.D.7    Yee, V.C.8    Weinshilboum, R.M.9
  • 49
    • 0026702428 scopus 로고
    • Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors
    • Yandle T, Richards M, Smith M, Charles C, Livesey J, Espiner E. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem. 1992;38:1785–1791.
    • (1992) Clin Chem , vol.38 , pp. 1785-1791
    • Yandle, T.1    Richards, M.2    Smith, M.3    Charles, C.4    Livesey, J.5    Espiner, E.6
  • 50
    • 0025277862 scopus 로고
    • Characterization of endopeptidase 3.4.24.11 (“enkephalinase”) activity in human plasma and cerebrospinal fluid
    • Spillantini MG, Sicuteri F, Salmon S, Malfroy B. Characterization of endopeptidase 3.4.24.11 (“enkephalinase”) activity in human plasma and cerebrospinal fluid. Biochem Pharmacol. 1990;39:1353–1356.
    • (1990) Biochem Pharmacol , vol.39 , pp. 1353-1356
    • Spillantini, M.G.1    Sicuteri, F.2    Salmon, S.3    Malfroy, B.4
  • 51
    • 28444443740 scopus 로고    scopus 로고
    • Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
    • Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA. 2005;102:17442–17447.
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 17442-17447
    • Hawkridge, A.M.1    Heublein, D.M.2    Bergen, H.R.3    Cataliotti, A.4    Burnett, J.C.5    Muddiman, D.C.6
  • 52
    • 79960584348 scopus 로고    scopus 로고
    • Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure
    • Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, Jaffe AS. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355–360.
    • (2011) Circ Heart Fail , vol.4 , pp. 355-360
    • Miller, W.L.1    Phelps, M.A.2    Wood, C.M.3    Schellenberger, U.4    Van Le, A.5    Perichon, R.6    Jaffe, A.S.7
  • 53
    • 84922777256 scopus 로고    scopus 로고
    • Unwinding the interaction of natriuretic peptides and neprilysin
    • Jaffe AS. Unwinding the interaction of natriuretic peptides and neprilysin. J Am Coll Cardiol. 2015;65:666–667.
    • (2015) J Am Coll Cardiol , vol.65 , pp. 666-667
    • Jaffe, A.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.